Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.
Leukemia-Lymphoma 2023
The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.
MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.
Why minimal residual disease testing is the "gold standard" for some patients and providers.
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Exousia Pro Orphan Drug Designation in Glioma
2
Sharing Insights Into a Multiple Myeloma Journey
3
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
4
How Breast Cancer Treatment Can Impact Menopause and Fertility
5
